Amidst Pressure From Activists, NY AIDS Institute Takes Landmark Step in HIV Prevention Pill Access
January 17, 2014
Eighteen months after the approval of Truvada (tenofovir/FTC) by the U.S. Food and Drug Administration as a pre-exposure prophylaxis (PrEP) regimen to prevent HIV transmission, the New York state AIDS Institute has released guidelines for health care professionals as to how to approach prescribing PrEP to people who wish to use the drug. Truvada is currently a part of many medication regimens for HIV-positive people, and is among the drugs used as post-exposure prophylaxis (PEP) for those who have had a potential exposure to HIV.
The guidance states that it was released after "studies evaluating the efficacy of PrEP have shown promising results." With the U.S. Centers for Disease Control and Prevention issuing only interim guidance on PrEP for specific populations, New York's guidelines are a welcome sign that adoption of PrEP may finally ramp up across the U.S.View Full Article
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)